Folate augmentation of antidepressant response

Drugs of Today

Volumn 49, Issue 12, 2013, Pages 791-798

  Owen, Richard T ^a  

^a NONE

Author keywords

Depression; Folate; L Methylfolate

Indexed keywords

ANTIDEPRESSANT AGENT; CYANOCOBALAMIN; FOLIC ACID; FOLIC ACID DERIVATIVE; FOLINIC ACID; LEVO METHYLFOLATE; PLACEBO; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DEMENTIA; DRUG SAFETY; DRUG TOLERABILITY; FOLIC ACID BLOOD LEVEL; HAMILTON ANXIETY SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OPEN STUDY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

DEPRESSION; FOLATE; L-METHYLFOLATE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FOLIC ACID; FOLIC ACID DEFICIENCY; HUMANS; LEUCOVORIN; TETRAHYDROFOLATES; TREATMENT OUTCOME;

EID: 84892740100     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.12.2086138     Document Type: Review

References (38)

1. rd Ed. American Psychiatric Association: Arlington, VA 2010.
2. Rush, A.J., Trivedi, M.H., Wisniewski, S.R et al. Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163(11): 1905-17.
3. Stahl, S. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry 2009, 70(11): 1493-4.
4. Nelson, J.C., Mazure, C.M., Jatlow, P.J. et al. Combining norepinephrine and serotonin reuptake mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004, 55(3): 296-300.
5. Blier, P., Ward, H.E., Tremblay, P. et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind, randomized study. Am J Psychiatry 2010, 167(3): 281-8.
6. Blier, P., Gobbi, G., Turcotte, J.E. et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009, 19(7): 457-65.
7. Rush, A.J., Trivedi, M.H., Stewart, J.W. et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind, randomized study. Am J Psychiatry 2011, 168(7): 689-701.
8. Blier, P. Combined treatments for depression as for other medical disorders (letter). Am J Psychiatry 2012, 169: 95.
9. Crellin, R., Bottiglieri, T., Reynolds, E.H. Folates and psychiatric disorders. Drugs 1993, 45(5): 623-36.
10. Stahl, S. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry 2008, 69(9): 1352-3.
11. Stahl, S. Enhancing outcomes from major depression-using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 2010, 15(2): 79-94.
12. 12 and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol 2005, 8: 523-8.
13. 12 and homocysteine in major depressive disorder. Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004, 65(8): 1090-5.
14. Papakostas, G.I., Petersen, T., Mischoulon, D. et al. Serum folate, vitamin B12 and homocysteine. Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004, 65(8): 1096-8.
15. Venkatasubramanian, R., Kumar, C.N., Pandey, R.S. A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes. J Affect Dis 2013, 150(2): 644-8.
16. 12 and serotonin levels in lymphocytes. Neuroimmunomodulation 2008, 15(3): 145-52.
17. Coppen, A., Bailey, J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo-controlled trial. J Affect Dis 2000, 60(2): 121-30.
18. Coppen, A., Chaudhry, S., Swade, C. Folic acid enhances lithium prophylaxis. J Affect Dis 1986, 10(1): 9-13.
19. Alpert, J.E., Mischoulon, D., Rubenstein, G.E.F., Bottonari, K., Nierenberg, A.A., Fava, M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002, 14(1): 33-38.
20. Godfrey, P.S.A., Toone, B.K., Carney, M.W. et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990, 336(8712): 392-5.
21. Passeri, M., Cucinotta, D., Abate, G. et al. Oral 5-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind controlled study. Aging Clin Exp Res 1993, 5(1): 63-71.
22. Di Palma, C., Urani, R., Agricola, R., Giorgetti, V., Dalla Verde, G. Is methylfolate effective in relieving major depression in chronic alcoholics? A hypothesis. Curr Ther Res 1994, 55(5): 559-68.
23. Guaraldi, G.P., Fava, M., Mazzi, F. et al. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry 1993, 5(2): 101-5.
24. Ginsberg, L.D., Oubre, A.Y., Daoud, Y.A. et al. L-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode. Innov Clin Neurosci 2011, 8(1): 19-28.
25. Papakostas, G.I., Shelton, R.C., Zajecka, J.M. et al. L-methylfolate as adjuvant therapy for SSRI-resistant major depression: results of two randomized, double-blind parallel-sequential trials. Am J Psychiatry 2012, 169(12): 1267-74.
26. Shelton, R.C., Solan Manning, J., Barrentine, L.W., Tipa, E.V. Assessing effects of L-methylfolate in depression management: results of a real-world patient experience trial. Prim Care Comp CNS Disord 2013, 15(4): e1-e6.
27. Willems, F.F., Boers, G.H., Blom, H.J. et al. Pharmacokinetic study on the utilization of 5-methyltetahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol 2004, 141(5): 825-30.
28. Levitt, M., Nixon, P.F., Pincus, J.H., Berlino, J.R. Transport characteristics of folates in CSF: a study utilizing 5-methytetrahydrofolate and 5-formyltetrahydrofolate. J Clin Invest 1971, 50(6): 1301-8.
29. 12, folic acid and the nervous system. Lancet Neurol 2006, 5(11): 949-60.
30. Stahl, S. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr 2007, 12(10): 739-44.
31. Venn, B.J., Green, T.J., Moser, R. et al. Comparison of the effect of low dose supplementation of L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized double-blind study. Am J Clin Nutr 2003, 77(3): 658-62.
32. Scott, J.M., Weir, D.G. The methyl folate trap: a physiological response in man to prevent methyl group deficiency in kwashiorkor and an explanation for folic acid induced exacerbation of subacute combined degeneration in pernicious anemia Lancet 1981, 2(8242): 337-40.
33. Troen, A.H., Mitchell, B., Sorensen, B. et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006, 136(10): 189-94.
34. Akoglu, B., Faust, D., Milovic, V. et al. Folate and chemoprevention of colorectal cancer: is 5-MTHF an active proliferative agent in folate-treated cancer cells? Nutrition 2001, 17(7-8): 652-3.
35. Frankenberg, F.R. Folate supplementation-is it safe and effective? (letter). J Clin Psychiaty 2009, 70(5): 767; reply:
36. Mischoulon, D., Fava, M., Stahl, S. J Clin Psychiaty 2009, 70(5): 767-8.
37. Wu, P., Pardridge, W.M. Blood brain barrier transport of reduced folic acid. Pharm Res 1999, 16(3): 415-9.
38. Aisen, P.S., Schneider, L.S., Sano, M. et al. High dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008, 300(15): 1774-83.